Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Maternal exposure before pregnancy, SARS-CoV-2 test
Clinical narrative: Maternal exposure before pregnancy; Positive Covid 5/15/22 on home Antigen test. Was treated with Paxlovid 5/16/22 x 5 days. Negative home antigen test following treatment. Pt has mild Covid symptoms on 5/31/22 following a Covid exposure 5/29/22. Patient is now has a Positive Home Anti; This spontaneous prospective pregnancy case was reported by a nurse and describes the occurrence of MATERNAL EXPOSURE BEFORE PREGNANCY (Maternal exposure before pregnancy) and COVID-19 (Positive Covid 5/15/22 on home Antigen test. Was treated with Paxlovid 5/16/22 x 5 days. Negative home antigen test following treatment. Pt has mild Covid symptoms on 5/31/22 following a Covid exposure 5/29/22. Patient is now has a Positive Home Anti) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Gestational diabetes, Prediabetes, Anxiety, Depression, Asthma, Migraine and Drug allergy. Concomitant products included INSULIN DETEMIR (LEVEMIR) from 25-Mar-2022 to an unknown date, ASPIRIN [ACETYLSALICYLIC ACID] from 24-Feb-2022 to an unknown date, ALBUTEROL [SALBUTAMOL] from 24-Feb-2022 to an unknown date, SERTRALINE from 23-Dec-2020 to an unknown date, CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) from 01-Nov-2021 to an unknown date and MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) from 14-Feb-2022 to an unknown date for an unknown indication.   On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on 06-Jan-2022 and the estimated date of delivery was 13-Oct-2022. On 15-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (Positive Covid 5/15/22 on home Antigen test. Was treated with Paxlovid 5/16/22 x 5 days. Negative home antigen test following treatment. Pt has mild Covid symptoms on 5/31/22 following a Covid exposure 5/29/22. Patient is now has a Positive Home Anti). On an unknown date, the patient experienced MATERNAL EXPOSURE BEFORE PREGNANCY (Maternal exposure before pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) during pregnancy.  The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 16-May-2022 to 20-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, MATERNAL EXPOSURE BEFORE PREGNANCY (Maternal exposure before pregnancy) outcome was unknown and COVID-19 (Positive Covid 5/15/22 on home Antigen test. Was treated with Paxlovid 5/16/22 x 5 days. Negative home antigen test following treatment. Pt has mild Covid symptoms on 5/31/22 following a Covid exposure 5/29/22. Patient is now has a Positive Home Anti) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-May-2022, SARS-CoV-2 test: positive (Positive) Positive on home antigen test. On 31-May-2022, SARS-CoV-2 test: positive (Positive) Positive home antigen test again. On an unknown date, SARS-CoV-2 test: negative (Negative) Negative home antigen test following treatment.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment medications were not reported.  Company Comment: This spontaneous prospective pregnancy case reported by a nurse concerns a 37-year-old female patient, with no relevant medical history, who experienced unexpected, non-serious AESI Covid19 approximately 6 months and 3 weeks after receiving a third dose of mRNA-1273.  Maternal exposure before pregnancy was also reported; she received the third dose of mRNA-1273 around 2 ½ months prior to becoming pregnant.  She was treated with a 5-day course of Nirmatrelvir/Ritonavir (Paxlovid).  However, around 9 days later, she had Covid19 exposure and developed mild Covid19 symptoms again around 2 days later. The ongoing Covid19 pandemic could be a contributory factor.  The benefit risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous prospective pregnancy case reported by a nurse concerns a 37-year-old female patient, with no relevant medical history, who experienced unexpected, non-serious AESI Covid19 approximately 6 months and 3 weeks after receiving a third dose of mRNA-1273.  Maternal exposure before pregnancy was also reported; she received the third dose of mRNA-1273 around 2 ½ months prior to becoming pregnant.  She was treated with a 5-day course of Nirmatrelvir/Ritonavir (Paxlovid).  However, around 9 days later, she had Covid19 exposure and developed mild Covid19 symptoms again around 2 days later. The ongoing Covid19 pandemic could be a contributory factor.  The benefit risk relationship of mRNA-1273 is not affected by this report.